A former Ballard Spahr LLP intellectual property partner has joined the ranks of Stevens & Lee PC outside Philadelphia to take on a new role as co-chair of the firm's technology, telecommunications and life sciences practice.
Alzheimer’s-focused biotechnology firm Alzheon Inc. said Wednesday it is no longer looking to go public, marking the second time the Framingham, Massachusetts-based company has canceled plans for an initial public offering in the past year.
Weil Gotshal & Manges LLP has amassed numerous wins in federal court in the past year — including a nearly $27 million jury win for Illumina Inc. in a patent suit — landing its life sciences team among Law360's Practice Groups of the Year.
Members of a New Jersey state appellate panel offered divergent views Wednesday on whether a lawyer had presented enough evidence to back up his class claims that homeopathic medicine from King Bio Inc. is falsely marketed as a treatment for the flu, a product he referred to as “a bottle of broken promises.”
Pfizer Inc. can’t enforce an arbitration clause that it never made its employees explicitly agree to, a New Jersey appeals court said Wednesday, clearing a former corporate flight attendant to sue for religious discrimination.
A pathologist fielded questions in a California courtroom Wednesday from jurors considering whether Johnson & Johnson baby powder contained asbestos that caused a dying woman’s cancer, explaining that the asbestos amounts found in the woman’s lung tissue and lymph nodes were too high to have come from ambient air.
The Missouri Supreme Court has granted Johnson & Johnson's last-minute bid to pause a trial on claims that asbestos in the pharmaceutical giant's talcum powder products gave 13 women ovarian cancer, issuing a stay days before jury selection was scheduled to begin in St. Louis.
Outcome Health named its first chief compliance officer Wednesday, tasking him with overhauling an existing compliance program as the Chicago startup tries to move past investor allegations that it overcharged drugmakers for the electronic advertisements it runs alongside medical information in doctors’ offices.
Pet medicine distributor PetIQ has urged a California federal court to toss an amended suit brought by two rivals seeking to block its purchase of a veterinary clinic chain, saying the antitrust suit lacks the flesh it was asked to add to the first version.
Bristol-Myers Squibb and Otsuka Pharmaceuticals asked a Florida federal judge Wednesday to require more than 550 plaintiffs to show why their claims should not be dismissed in the multidistrict legislation over the antipsychotic drug Abilify's side effects after they failed to submit plaintiff profile forms.
The Third Circuit on Wednesday affirmed that a Chubb Ltd. insurer doesn’t have to cover Tela Bio Inc.’s costs to defend against a trade secrets and unfair competition lawsuit brought by rival LifeCell Corp. over a hernia treatment product, agreeing with a lower court that the underlying action doesn’t contain any potentially covered defamation claims.
Johnson & Johnson told a Pennsylvania federal judge Tuesday that Walgreens and Kroger can't bring antitrust claims against it for allegedly inflating prices and suppressing competition for its drug Remicade, reiterating its argument that the retailers didn't directly purchase the drug from J&J.
The Sixth Circuit should decide whether Racketeer Influenced and Corrupt Organizations Act and nuisance claims in multidistrict litigation over the opioid crisis hold up before the Ohio district court case moves on, drug distributors have told the trial court.
A class of shareholders suing pharmaceutical maker Insys Therapeutics Inc. and its directors over an alleged scheme to market a powerful opioid for off-label uses asked the Delaware Chancery Court to lift the stay in the proceedings to allow a motion to dismiss to move forward.
The ex-husband of a former Ariad Pharmaceuticals executive was sentenced to 18 months in prison Wednesday for insider trades he made based on meetings his then-wife had with the U.S. Food and Drug Administration about the company's cancer drug.
The day before hundreds of potential jurors descend on a Boston courtroom for a closely watched criminal case accusing former Insys Therapeutics Inc. executives of bribing doctors to prescribe opioids, attorneys sparred Wednesday over what patients who took the drug can say during the 14-week trial.
The New York attorney general on Tuesday asked a state court to force drug company Mallinckrodt PLC to hand over documents related to a federal investigation of the company's marketing of opioids as part of its own investigation into the company's practices.
Oncology-focused biopharmaceutical firm INmune Bio Inc. on Wednesday said it intends to raise up to $20 million from an initial public offering guided by Sichenzia Ross Ference LLP, as it looks to fund ongoing research and drug development activities.
Paul Weiss Rifkind Wharton & Garrison LLP scored a Federal Circuit win for Vanda Pharmaceuticals that led to new patent guidance, successfully defended Fresenius' decision to cancel its $4.8 billion Akorn buy and kept a Genentech hemophilia treatment from being booted from the market, landing the firm among Law360's Life Sciences Groups of the Year.
A court filing by Massachusetts Attorney General Maura Healey on Tuesday revealed new information about the inner workings of Purdue Pharma and its controlling Sackler family as they marketed OxyContin over the past two decades, including harsh statements by executives that point to a strategy of blaming drug users for addiction to the painkiller.
Alternative fee agreements can help align law firm and client interests, increase efficiency and eliminate corporate extortion, among other benefits. They are the best thing to happen to the practice of law in decades, says Kelly Eisenlohr-Moul at Dinsmore & Shohl LLP.
In New Haven v. Purdue, a Connecticut state judge ruled last week that opioid manufacturers are not liable for cities' emergency and social services costs. This decision protects liability insurance from being transformed into a funding mechanism for social problems that it was not designed to cover, say Patrick Bedell and Kevin Harris of BatesCarey LLP.
In this installment of their four-part series, attorneys at Skadden Arps Slate Meagher & Flom LLP offer insights to companies on executive compensation matters for 2019 — including pay ratio and hedging disclosures, say-on-pay votes and changes in pay practices due to the Tax Cuts and Jobs Act.
Under a no-deal Brexit scenario, all provisions of EU law will no longer apply to the U.K., with potentially chaotic results for the life sciences industry. In particular, the impact on marketing authorizations could be highly disruptive, say attorneys at Latham & Watkins LLP.
Each company faces important decisions in preparing for its 2019 annual meeting and reporting season. This four-part series by attorneys at Skadden Arps Slate Meagher & Flom LLP covers essential items on which companies should focus, including corporate governance, executive compensation and disclosure matters.
Last week, the U.S. Supreme Court denied certiorari in two major False Claims Act cases, both involving the government’s knowledge or suspicion of violations allegedly resulting in knowingly false claims. Nichols Liu LLP attorneys consider the implications for the materiality standard and FCA cases going forward.
In 2018, the Trump administration took few concrete steps that will significantly impact drug prices in the near future. The most consequential ideas lack political support, while the more feasible ideas are unlikely to change much, say attorneys at Ropes & Gray LLP.
Can lawyers lead a revolution? According to "The Clamor of Lawyers: The American Revolution and Crisis in the Legal Profession" — a slim but elegant volume by Peter Charles Hoffer and Williamjames Hull Hoffer — they can and they did, says First Circuit Judge David Barron.
The U.S. Tax Court recently expanded the application of Internal Revenue Code Section 280E, disallowing certain deductions, to include an S corporation acting as a dispensary's “management” company. In response, cannabis companies may want to weigh the tax risks and potential benefits of alternate planning strategies, says Justin Hobson at Lane Powell PC.
President Donald Trump’s approach to crisis communications has changed the game enough to demand companies' consideration of a whole new set of options. John Hellerman of Hellerman Communications and Bill Pittard of KaiserDillon PLLC discuss whether corporations can successfully use similar tactics.